Summary of Industry Reports Industry: Pharmaceutical and Biotechnology Key Points from Document 1 1. **Raw Material Supply Changes**: The supply of raw materials is accelerating, with a focus on subsequent volume and price changes [1] 2. **Global GLP-1 Landscape**: The global GLP-1 landscape is continuously evolving, and Chinese companies are still pursuing international expansion [1] 3. **Small Nucleic Acid Sector**: Leading companies are gradually entering the small nucleic acid field, with market progress expected to drive the development of supporting industrial chains [1] 4. **Retail Pharmaceutical Market Outlook**: The retail pharmaceutical market is expected to improve by Q4 2025, with an enhanced positioning of chain pharmacies [1] 5. **Value of Oral Immunomodulatory Drugs**: Emphasis on the market value of oral immunomodulatory drugs [1] 6. **Investment Recommendations**: Recommended companies include Chuaning Biological, with attention to Lianbang Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, as well as synthetic biology companies [1] 7. **CXO Order Trends**: Positive trends in CXO orders and rising prices for safety evaluation orders, with recommendations for Yinos and Zhaoyan New Drug, and recommendations for Weiya Biological and Puris [1] Key Points from Document 2 1. **Small Nucleic Acids Breakthrough**: Continuous breakthroughs in small nucleic acids, with ongoing progress in external authorizations by Chinese companies, recommending Yuekang Pharmaceutical and Sunshine Novo [2] 2. **Self-Immunity Field**: Focus on breakthroughs in oral directions and difficult-to-treat areas like UC/IBD, recommending Yahong Pharmaceutical and Yifang Biological [2] 3. **GLP-1 Weight Loss Authorizations**: Recommendations for Zhongsheng Pharmaceutical in the GLP-1 weight loss field, with attention to Lianbang Pharmaceutical and Shiyao Group [2] 4. **ZAP-X Radiation Therapy Equipment**: Initiation of domestic clinical research for ZAP-X radiation therapy equipment, recommending Baiyang Pharmaceutical [2] 5. **Policy Support for Brain-Computer Interface Technology**: Support for the development of invasive brain-computer interfaces, recommending Meihao Medical and Botuo Biological, with accelerated approvals for non-invasive devices, focusing on Xiangyu Medical and Kefu Medical [2] 6. **High-Value Medical Device Exports**: Breakthroughs in exports of high-value medical consumables, with attention to Chunli Medical, Aikang Medical, Nanwei Medical, and Baixin An [2] 7. **AI in Healthcare**: Accelerated applications of AI in healthcare, reshaping application scenarios and bringing changes in industrial chain value, recommending Anbiping and focusing on Yuyue Medical and Meinian Health [2] 8. **Chain Pharmacy Industry**: Industry consolidation in chain pharmacies, with policy support for enhanced positioning, recommending Yifeng Pharmacy and Laobaiqing, with attention to Yixintang [2]

Core Viewpoint - The Hong Kong stock market showed strong performance in the early session, particularly in the innovative drug sector, indicating a robust demand for pharmaceuticals and a shift towards an "innovation-driven" revenue era in the industry [1] Group 1: Market Performance - Innovative drug stocks performed well, with notable gains: Zai Lab rose over 6%, CanSino Biologics-B increased over 5%, and Rongchang Biologics climbed over 4% [1] - The Hong Kong Innovative Drug ETF (159567) rose over 2%, reflecting the positive sentiment in the sector [1] Group 2: Industry Insights - Analysts attribute the pharmaceutical industry's ability to reach new highs despite ongoing challenges to the continuous demand for medical solutions and the increasing number of unmet needs [1] - Pharmaceutical companies are significantly increasing their R&D investments to address these unmet needs, positioning China as a key player in global innovative drug development [1] - The trend of overseas licensing has been rising year after year, further emphasizing the industry's shift towards innovation [1] Group 3: Investment Opportunities - The Hong Kong Innovative Drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, aiming to reflect the performance characteristics of listed companies in the innovative drug sector [1] - Investors can also access the Hong Kong Innovative Drug ETF through linked funds (Class A: 023929, Class C: 023930) to capitalize on the upward opportunities in the sector [1]

Market Overview - The Hang Seng Index is expected to hold at 26,000 points, with the U.S. Federal Reserve's hawkish stance influencing market dynamics and leading to a rebound in the U.S. dollar index [2] - The Chinese government is anticipated to focus on expanding domestic demand and technological self-sufficiency in 2026, with GDP growth targets expected to be set between 4.5% and 5% [2] - Regulatory measures are being implemented to cool the market, including increased financing margin ratios and a reduction in leverage across major exchanges [2] Company News - Alphabet plans to issue high-rated U.S. bonds to raise approximately $15 billion, continuing the trend of significant debt issuance among companies investing heavily in AI infrastructure [4][10] - Alibaba's Gaode Dache has been summoned by the Ministry of Transport due to issues related to price management and operational oversight [4][10] - BYD has filed a lawsuit against the U.S. government seeking the return of all tariffs imposed [4] - Hong Kong Telecom reported a 4% increase in profit for the previous year, with a dividend of 47.97 cents [4] Sector Focus - The travel sector is expected to see strong demand as the Lunar New Year approaches, with an estimated 2,200 inbound tours from mainland China to Hong Kong, involving around 86,000 visitors [9] - The semiconductor industry is projected to experience significant growth driven by strong demand for AI technologies [7] - The logistics sector in China reported a total logistics volume of 368.2 trillion yuan for 2025, reflecting a year-on-year growth of 5.1% [8] Economic Indicators - The U.S. Federal Reserve maintained interest rates in January, indicating a cautious approach to future adjustments based on economic data [5] - The international oil market is expected to face upward pressure on prices due to geopolitical factors, despite an oversupply situation [5] - The Chinese central bank is expected to inject liquidity into the market ahead of the Lunar New Year, with estimates suggesting a liquidity gap of over 3 trillion yuan [8]

Major Events - Xian Dao Intelligent (00470) has set the offer price for H-shares at HKD 45.80, with the sale volume adjustment rights fully exercised [1] - Lexin Outdoor (02720) has seen a public offering subscription rate of 3654.23 times, with a per share pricing of HKD 12.25 [1] - Aixin Yuan Zhi (00600) has achieved a public offering subscription rate of 104.82 times, with a final offer price of HKD 28.2 per share [1] - Shandong Xinhua Pharmaceutical (00719) has obtained the registration certificate for glucosamine sulfate capsules [1] - United Pharmaceutical (03933) has passed the consistency evaluation for roxithromycin capsules [1] - InnoCare Pharma (03696) has reached several drug development projects in the central nervous system and autoimmune disease fields with Kangzhi Pharmaceutical, valued at tens of millions of HKD [1] - Sunshine Insurance (06963) subsidiary plans to increase capital to Sunshine Asset Management (Hong Kong) for a total of no more than HKD 1 billion [1] - Crystal Tech Holdings (02228) has established a robotics laboratory in BASF, receiving top endorsement from the chemical industry for global technological leadership [1] - Youjia Innovation (02431) has newly secured designated projects in intelligent driving and intelligent cockpit [1] - China Resources Pharmaceutical (03320) is considering the potential sale of approximately 17.87% equity in Tianmai Biotechnology [1] Operating Performance - Hong Kong Telecom-SS (06823) reported a profit attributable to shareholders of HKD 5.286 billion for 2025 [1] - Pop Mart (09992) has achieved global sales of over 400 million units across all IP and product categories in 2025 [1] - Longfor Group (00960) reported a contract sales amount of HKD 2.45 billion in January [1] - China Jinmao (00817) recorded a signed sales amount of HKD 7.603 billion in January, an increase of 13.56% year-on-year [1] - New天绿色能源 (00956) completed a power generation volume of 1.7393 million MWh in January, a year-on-year increase of 15.25% [1] - Dekang Agriculture and Animal Husbandry (02419) sold 1.04236 million pigs in January [1] - China Oriental Education (00667) has issued a profit warning, expecting a year-on-year profit increase of 46% to 51% for the 2025 fiscal year [1] - China Nuclear International (02302) has issued a profit warning, expecting gross profit for 2025 to reach no less than approximately HKD 260 million [1] - Mingyuan Cloud (00909) has issued a profit warning, expecting net profit attributable to shareholders for 2025 to be approximately HKD 26.9 million to HKD 32.8 million, turning from loss to profit year-on-year [1]

Core Viewpoint - The article discusses the acceleration of Chinese innovative drugs entering the high-value medical segment of obesity treatment, particularly focusing on the approval of UBT251 for the treatment of moderate to severe obstructive sleep apnea (OSA) [4][5]. Group 1: UBT251 Development - UBT251, developed by Federated Pharmaceuticals, has received approval from the National Medical Products Administration to conduct clinical trials for OSA, expanding its indication [4]. - UBT251 targets three metabolic pathways: GLP-1, GIP, and GCG, which allows for a synergistic effect on energy intake, weight, and metabolic status, differentiating it from current single or dual-target GLP-1 products [5]. - In a 12-week Phase 1b clinical trial, patients in the highest dose group experienced an average weight loss of 15.1%, with good safety and tolerability [5]. Group 2: OSA as a Target Condition - OSA is a chronic disease that has been underestimated, characterized by repeated airway collapse during sleep, leading to significant health risks such as hypertension, arrhythmias, and metabolic diseases [7]. - Traditional treatments relying solely on CPAP machines are insufficient to address the systemic metabolic issues associated with OSA [7]. - The approval of UBT251 for OSA clinical research aligns with the growing evidence that metabolic interventions can improve outcomes for OSA patients [7].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry, indicating a positive outlook for investment opportunities in this sector [3]. Core Insights - The commercialization of Antibody-Drug Conjugates (ADC) is accelerating, with 20 ADC drugs approved globally, and 6 of them consistently generating over $1 billion in revenue for two consecutive years. The competition in the ADC market is entering a new phase, with approximately 60 ADC drugs currently in clinical phase 3 or awaiting market approval [6][30]. - Domestic innovative pharmaceutical companies are adopting various strategies for ADC capacity layout, with companies like Rongchang Biopharma transitioning from outsourcing to in-house production, while others like Kelong Biotechnology are building their own production bases [6][31]. - The recent revision of the "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" supports segmented contract manufacturing and commercial-scale drug sales, providing a foundation for ADC commercialization partnerships [6][32]. Market Performance - The pharmaceutical index rose by 0.14% this week, outperforming the CSI 300 index by 1.47 percentage points, ranking 15th in industry performance [10]. - Since the beginning of 2026, the pharmaceutical index has increased by 3.28%, again outperforming the CSI 300 index by 2.99 percentage points, ranking 23rd [10]. - The best-performing sub-sector this week was Traditional Chinese Medicine, which increased by 2.56%, while Chemical Pharmaceuticals and Biological Products saw declines of 0.62% and 1.82%, respectively [15][17]. Stock Performance - Among A-share pharmaceutical stocks, the top five performers this week were Guangshengtang (+29.83%), Haixiang Pharmaceutical (+18.64%), and Meidixi (+18.04%) [20]. - In the Hong Kong market, the top performers included Yiteng Jiahe (+14%) and Kedi-B (+9.96%), with 38 out of 116 pharmaceutical stocks rising, representing 32.76% [24][25]. Industry News and Policies - The inclusion of implantable brain-machine interfaces in the category of Class III medical devices marks a significant regulatory development, indicating a focus on innovative medical technologies [27]. - Novartis has submitted an application for the marketing of Ianalumab in China, a drug targeting various autoimmune diseases, which has shown promising results in clinical trials [27]. - Johnson & Johnson announced the approval of Daratumumab injection for a new combination therapy in China, providing a new treatment option for multiple myeloma patients [28].

Core Viewpoint - The company has successfully passed the consistency evaluation for the generic drug Roxithromycin capsules (150mg) by the National Medical Products Administration of China, which will strengthen its position in the anti-infection sector [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., has received approval for Roxithromycin capsules, marking it as the first company to pass this evaluation for this dosage form [1] - Roxithromycin is a second-generation macrolide antibiotic known for its good acid resistance, broad antibacterial spectrum, strong tissue penetration, and low incidence of adverse reactions [1] Group 2: Clinical Applications - The drug is clinically applicable for treating infections caused by Roxithromycin-sensitive pathogens in areas such as otolaryngology, respiratory tract, skin and soft tissue, and urogenital infections [1] Group 3: Market Position and Future Prospects - The product is listed as a Class B drug in the National Medical Insurance Directory (2025 version), which may enhance its market accessibility [1] - The approval is expected to help the company consolidate its competitive advantage in the anti-infection field and drive further product development, potentially leading to greater returns for the company and its shareholders [1]

Core Viewpoint - The company has successfully passed the consistency evaluation for the generic drug Roxithromycin capsules (150mg) through the National Medical Products Administration of China, reinforcing its competitive position in the anti-infection sector [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., has received approval for Roxithromycin capsules, marking it as the first enterprise to pass the consistency evaluation for this formulation [1] - Roxithromycin is a second-generation macrolide antibiotic known for its acid resistance, broad antibacterial spectrum, strong tissue penetration, and low incidence of adverse reactions [1] Group 2: Clinical Applications - Roxithromycin capsules are clinically applicable for treating infections caused by Roxithromycin-sensitive pathogens, including those affecting the ear, nose, throat, respiratory tract, skin, soft tissues, and urogenital tract [1] Group 3: Market Position and Future Outlook - The product is listed as a Class B drug in the National Medical Insurance Directory (2025 version), which is expected to enhance the company's market position in the anti-infection field [1] - The company aims to continue its commitment to new product development, anticipating greater returns for itself and its shareholders [1]

Core Viewpoint - The approval of the roxithromycin capsules by the National Medical Products Administration of China enhances the company's competitive position in the anti-infection sector and is expected to generate greater returns for the company and its shareholders [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., has successfully passed the consistency evaluation of the roxithromycin capsules (150mg) [1] - Roxithromycin capsules are a second-generation macrolide antibiotic known for their acid resistance, broad antibacterial spectrum, strong tissue penetration, and low incidence of adverse reactions [1] - The product is currently listed as a Class B drug in the National Medical Insurance Directory (2025 version) [1] Group 2: Market Position and Future Prospects - The company is the first to pass the consistency evaluation for the roxithromycin capsule formulation [1] - This approval will further help the company consolidate its advantageous position in the anti-infection field [1] - The company is committed to ongoing new product development, which is anticipated to create greater benefits for the company and its shareholders [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本次獲批將進一步有助於本公司鞏固於抗感染領域的優勢地位。本公司將持續致力於 新產品研發，預期將為本公司及其股東創造更大收益。 承董事會命 聯邦制藥國際控股有限公司 主席 蔡海山 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 ( 於開曼群島成立之有限公司 ) (股份代號: 3933) 本集團產品羅紅霉素膠囊通過一致性評價 本公告乃由聯邦制藥國際控股有限公司（「本公司」）自願發出。 本公司董事會（「董事會」）欣然公佈，本公司全資附屬公司珠海聯邦制藥股份有限公 司中山分公司申報的羅紅霉素膠囊（規格：150mg）通過中國國家藥品監督管理局仿 製藥質量和療效一致性評價（「一致性評價」）。 羅紅霉素膠囊是第二代大環內酯類抗生素，具有耐酸性好、抗菌譜廣、組織穿透性強、 不良反應發生率較低等顯著抗感染優勢。臨床適用於治療由羅紅霉素 ...